Michael Kalfas and Paul Leeks summarise a recent Danish study that assesses the risk of antidepressant-induced mania in patients with bipolar depression.
[read the full story...]
Holly Fraser discusses new findings on whether and how we can predict antidepressant response using artificial intelligence.
[read the full story...]
Kam Bhui reviews a conceptual framework developed to understand structural racism and suicide prevention for ethnoracially minoritised youth in the United States.
[read the full story...]
Vishal Bhavsar reviews a recent study examining correlates of future violent behaviour in people being treated for schizophrenia in US-based treatment centres.
[read the full story...]
Emmeline Lagunes Cordoba and Derek Tracy explore a case control study that looks at cognitive change in people with schizophrenia and other psychoses in the decade following the first episode.
[read the full story...]
Keir Harding prepares for the #BIGSPD19 conference by reading Mike Crawford et al’s recent RCT on the clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder.
[read the full story...]
Dafni Katsampa explores a recent prospective cohort study that investigates the association between smoking behaviour and cognitive functioning in patients with psychosis, their siblings and healthy control subjects.
[read the full story...]
Luke Sheridan Rains publishes his debut blog on a recent multicentre RCT of Cannabidiol (CBD) as an adjunctive therapy for people with schizophrenia, which suggests that CBD had a beneficial, but modest impact on positive psychotic symptoms and severity of illness when used alongside existing antipsychotics.
[read the full story...]
Donncha Mullin summarises a recent meta-analysis of prospective cohort studies, which establishes a strong link between exercise and depression.
[read the full story...]
Students and Teachers from the King’s College London PNoMH Distance Learning MSc summarise a major new meta-analysis that brings together the last 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia.
[read the full story...]
